Invivyd to Host Conference Call Discussing Full Year 2022 Financial Results and Business Highlights

Rhea-AI Summary

Invivyd, Inc. (Nasdaq: IVVD) announced a conference call scheduled for March 23, 2023, at 4:30 p.m. ET. The call will discuss its financial results for the year ended December 31, 2022, alongside recent business highlights. Invivyd is focused on developing antibody-based therapies targeting serious viral threats, notably SARS-CoV-2. The company employs advanced techniques in evolutionary virology and antibody engineering to create long-lasting antibodies to counteract viral escape. Investors and analysts can register for the call and access a replay via the company's investor website.

WALTHAM, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced that it will host a conference call on Thursday, March 23, 2023, at 4:30 p.m. ET to discuss its financial results for the full year ended December 31, 2022, and recent business highlights.

Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the company’s investor website approximately two hours after the call’s conclusion. Those who plan on participating are advised to join 15 minutes prior to the start time.

About Invivyd
(Nasdaq: IVVD)

Invivyd, Inc., is a biopharmaceutical company on a mission to rapidly and perpetually deliver antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, beginning with SARS-CoV-2. Invivyd's technology works at the intersection of evolutionary virology, predictive modeling, and antibody engineering, and is designed to identify high-quality, long-lasting antibodies with a high barrier to viral escape. The company is generating a robust pipeline of product candidates which could be used in prevention or treatment of serious viral diseases, starting with COVID-19 and expanding into influenza and other high-need indications. Visit https://invivyd.com/ to learn more.

Media Contact:
Kate Burdick, Evoke Canale
860-462-1569
kate.burdick@evokegroup.com

Investor Contact:
Chris Brinzey, ICR Westwicke
339-970-2843
chris.brinzey@westwicke.com

FAQ

When will Invivyd discuss its 2022 financial results?

Invivyd will discuss its financial results for the full year ended December 31, 2022, during a conference call on March 23, 2023, at 4:30 p.m. ET.

How can I participate in Invivyd's conference call?

Listeners can register for the conference call via the provided webcast link, and analysts can join the question and answer session via a separate link.

What is Invivyd, Inc. focused on?

Invivyd, Inc. focuses on developing antibody-based therapies to protect against serious viral diseases, starting with COVID-19 and expanding to other viral threats.

What is the stock symbol for Invivyd?

The stock symbol for Invivyd is IVVD.